

Jan. 17, 2023

Company: Chiome Bioscience Inc.

Representative: Shigeru Kobayashi, President & CEO

(Code: 4583, Tokyo Stock Exchange Growth)

Termination of the License Agreement for anti-TROP-2 antibody development and commercialization

Chiome Bioscience Inc. ("Chiome") announced today that it has agreed to terminate the License Agreement for anti-TROP-2 antibody development and commercialization ("this agreement") with Shanghai Henlius Biotech, Inc. ("Henlius").

Under this agreement, Chiome had granted an exclusive license, with sublicensing rights, to Henlius concerning development, manufacturing and marketing in China (including Hong Kong Special Administrative Region and Macau Special Administrative Region and Taiwan region) for LIV-2008/2008b. In addition, Chiome had granted to Henlius option rights concerning development, manufacturing and marketing of LIV-2008/2008b in the rest of the world other than the initial territory. Chiome had received an upfront payment upon signing this agreement.

After the conclusion of this agreement, Henlius had been considering development formats for the LIV-2008/2008b. However, due to competition condition of similar products in the market and the consideration of commercial feasibility, Henlius decided not to further develop the LIV-2008/2008b and to terminate this agreement with Chiome.

In our drug discovery business, Chiome are actively engaged in licensing activities for our drug discovery pipeline, such as CBA-1205/CBA-1535/PCDC, to make new contracts. In the future, we will also promote licensing activities for LIV-2008/2008b to potential out-licensing companies.

There is no impact on the financial performance in the fiscal period ending December 31, 2023. There is also no change to the our target of achieving profitability in operating income for a single fiscal year from 2023 to 2025.

【Inquiries】

Chiome Bioscience Inc. Investor Relations

E-mail: ir@chiome.co.jp